ACTRN12621001704886
Recruiting
未知
Imaging of Metastatic Prostate Cancer Tumors Using 68Ga-NTA-14
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Metastatic Prostate Cancer
- Sponsor
- St. Vincent's Hospital Sydney Limited
- Enrollment
- 10
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male, aged 18 years or older
- •Histologically confirmed diagnosis of prostate cancer that is metastatic and castration resistant
- •Rising PSA (greater than or equal to 2 ng/dL over nadir) following curative intent therapy (surgery) or radiographic disease progression by traditional imaging (CT/MRI/bone scan)
- •Signed, written informed consent
- •Completed or undergoing treatment for mCRPC and are being considered for clinical 177Lu\-PSMA I\&T treatment.
- •Participants must have adequate renal function: Creatinine clearance or estimated glomerular filtration rate greater than or equal to 35 mL/min/1\.73 m2 .
Exclusion Criteria
- •Participants who cannot lie still for at least 30 minutes or comply with imaging procedures and study requirements.
- •Participants who are not suitable for 177Lu\-PSMA I\&T treatment based on investigator discretion.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Diagnostic imaging in prostate cancer (as in tumours with accelerated menbrane turn-over)by F-18 Fluoro-metil-choline PET/CTpatients with prostate cancer istologically provenMedDRA version: 14.1Level: SOCClassification code 10038359Term: Renal and urinary disordersSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: SOCClassification code 10022891Term: InvestigationsSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2008-003337-24-ITCENTRO DI RIFERIMENTO ONCOLOGICO DI BASILICATA
Completed
Not Applicable
Novel Imaging in Staging of Primary Prostate CancerHigh Risk Prostate CancerNCT03537391Turku University Hospital80
Recruiting
Not Applicable
Evaluation of new PET tracer, [F-18]Florastamin for diagnosing prostate cancer: Phase I clinical trialKCT0004817FutureChem10
Active, not recruiting
Phase 1
Imaging of the prostate tumors using PET/CT and PET/MRI with the ligand of the prostatic specific membrane antigene 68Ga-PSMA-11prostatic carcinoma higly suspected or its staging or restagingTherapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]EUCTR2017-004128-32-CZFakultní nemocnice Plzen200
Recruiting
Not Applicable
Evaluation of new PET tracer, [F-18]Florastamin for diagnosing prostate cancerNeoplasmsKCT0003924Korea Cancer Center Hospital6